Carly Forster

About the Author Carly Forster

Content Manager at TipRanks. Earned a Bachelor of Arts Degree with a Major in Communications at the University of California, San Diego.

Looking Ahead of Wall Street: Tesla Motors Inc (TSLA), Xoma Corp (XOMA), Walt Disney Co (DIS), Intercept Pharmaceuticals Inc (ICPT)

Wall Street has an exciting week ahead as earnings season continues to roll on with Tesla Motors Inc (NASDAQ:TSLA), Xoma Corp (NASDAQ:XOMA), Walt Disney Co (NYSE:DIS), and Intercept Pharmaceuticals Inc (NASDAQ:ICPT) all slated to announce quarterly earnings results. Here’s what investors should look for:

Tesla Motors Inc

Electric vehicle maker Tesla will announce second quarter 2015 earnings results on Wednesday, August 5, after market close. The Street expects the company to post a loss of ($0.59) per share on $1.17 billion in revenue, a dramatic fall from $0.11 earnings per share but up from $857.51 million in revenue from the same quarter a year prior.

It’s been an exciting year for Tesla as the company has unveiled the Tesla Powerwall, a rechargeable solar-powered home battery, and provided updates on new Tesla models and the gigafactory. Investors will likely be looking for an update on the company’s third quarter guidance, outlook for the rest of the year, and projections for the new Model X SUV.

More specifically, investors are looking to see if Tesla is on the path of meeting its expected 2015 delivery of 55,000 vehicles. If the company meets this projection, it would mark a 74% year-over-year growth in vehicle sales, up from a 41% increase in 2014.

Tesla planned to complete 40% of the vehicle deliveries in the first half of the year. The company has done a good job staying in line with this goal, having delivered 39% of the 55,000 vehicles this year so far. With that said, the company still has a long way to go, having to deliver 33,500 vehicles in the second half of the year to meet its goal. If Tesla’s projection is reached, it will mark a 90% increase in vehicle sales year-over-year.

Out of 12 analysts polled by TipRanks, 7 analysts are bullish on Tesla, 3 are bearish, and 2 are neutral. The average 12-month price target for Tesla is $311.00, marking a 16.85% potential upside from where the stock last closed. On average, the all-analyst consensus for Tesla is Hold.

TSLA

Xoma Corp

Pharmaceutical company Xoma Corp is slated to announce second quarter 2015 earnings results on Thursday, August 6, after market close. The Street expects the company to post a loss of ($0.18) per share on $4.38 million in revenue, down from a loss of ($0.14) per share on $5.97 million in revenue year-over-year.

Xoma Corp recently released results from the Phase 3 EYEGUARD-B trial in mid-July, in which the company tested its pipeline treatment gevokizumab. While analysts expected Xoma to report top-line results, the company ultimately missed its primary endpoint. As a result, the stock dropped over 70% following the news on July 22.

This is not the first time Xoma has missed its primary endpoint in a late stage trial. Consequently, the company has brought experimental medications through the testing process several times.

Out of 7 analysts polled by TipRanks, only 1 analyst is bullish on Xoma Corp and 6 are neutral. The average 12-month price target for Xoma is $5.25, marking an overwhelming 619.18% potential upside from where the stock last closed.

XOMA

Walt Disney Co

International family entertainment and media enterprise, Walt Disney Co, is scheduled to announce fiscal third quarter 2015 earnings results on Tuesday, August 4, after market close. The Street expects the company to post earnings of $1.42 per share and $13.22 billion in revenue, up from $1.28 earnings per share and $12.47 billion in revenue from the same quarter last year.

Disney is having a pretty decent year so far, having launched three of the six highest grossing films of 2015 and having posted record attendance at its theme parks. Additionally, ESPN remains the clear leader in sports networks.

However, some believe it may be a slow quarter for Disney as the company won’t see revenue from its hit summer movies like Inside Out and Ant-Man until its next quarterly earnings report after each film’s multiplex run. Additionally, the upcoming earnings report will be compared to the same quarter last year in which Disney’s overwhelmingly successful animated movie Frozen became available on DVD and Blu-ray.

It is also expected that the company’s theme park attendance will decrease compared to the quarter prior due to the lack of school breaks in the June quarter.

However, investors (and fans) are getting excited for the release of the highly anticipated new Star Wars movie, slated to hit theaters this December. The film is expected to rake in big numbers but the earnings from the film will not be reflected until fiscal 2016 on Disney’s calendar.

Out of 15 analysts polled by TipRanks, 12 analysts are bullish on Disney and 3 are neutral. The average 12-month price target for Disney is $119.86, marking a -0.12% potential downside from where the stock last closed. On average, the all-analyst consensus for Disney is Moderate Buy.

DIS

Intercept Pharmaceuticals Inc

Bio-pharmaceutical company Intercept Pharma will announce second quarter 2015 earnings results on Wednesday, August 5, after market close. The Street estimates the company to post a loss of ($2.00) per share.

On June 29, the biopharmaceutical company announced it had completed a New Drug Application for OCA in PBC. Obeticholic acid, or OCA, is a treatment for patients with the liver disease PBC. OCA has received fast-track designation in the United States and orphan drug designation in both the U.S. and Europe. The FDA now has about one more month to review the application.

Out of 11 analysts polled by TipRanks, 8 analysts are bullish on Intercept Pharmaceuticals and 3 are neutral. The average 12-month price target for Intercept is $399.82, marking a 51.56% potential upside from where the stock last closed. On average, the all analyst consensus for Intercept Pharmaceuticals is Moderate Buy.

ICPT